Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted Radiation, Pluvicto, and Testosterone Replacement in mCRPC
NCT06084338Phase 2Recruiting
- Sponsor
- VA Office of Research & Development
- Start
- Dec 2023
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Testosterone TEPI patch in metastatic castration-resistant prostate cancer (mCRPC), sponsored by VA Office of Research & Development. Started Dec 2023; status: recruiting.
02
Drugs
Testosterone TEPI patch
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06084338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06084338.